Crossmark

Survival impact of adjuvant capecitabine in triple-negative breast cancer Latin American patients with residual disease: a real-world study

Crossref DOI link: https://doi.org/10.1007/s10549-025-07814-3

Published Online: 2025-09-16

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Graciano, Noiver https://orcid.org/0000-0001-7715-9704
López, Lucelly https://orcid.org/0000-0002-1534-520X
Rodriguez, Carlos A. https://orcid.org/0000-0002-4042-4313
Montoya, Katherine https://orcid.org/0009-0002-9414-076X
Cortés, Javier https://orcid.org/0000-0001-7623-1583
License Information

Text and Data Mining valid from 2025-09-16

Version of Record valid from 2025-09-16
More Information

Article History

Received: 23 June 2025

Accepted: 19 August 2025

First Online: 16 September 2025

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.